

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Draxxin Plus 100 mg/ml + 120 mg/ml solution for injection for cattle

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

#### **Active substances:**

Tulathromycin 100 mg  
Ketoprofen 120 mg

#### **Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Monothioglycerol	5 mg
Propylene glycol	
Citric acid (E-330)	
Hydrochloric acid, concentrated (for pH adjustment)	
Sodium hydroxide (for pH adjustment)	
Pyrrolidone	
Water for injections	

Clear colourless to yellow / green-yellow solution. Free from visible particles

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cattle.

#### **3.2 Indications for use for each target species**

Treatment of bovine respiratory disease (BRD) associated with pyrexia due to *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* susceptible to tulathromycin.

#### **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use simultaneously with other macrolides or lincosamides (see section 3.4).

Do not administer to animals suffering from gastrointestinal lesions, haemorrhagic diathesis, blood dyscrasia or hepatic, renal or cardiac conditions.

### **3.4 Special warnings**

Cross resistance occurs with other macrolides. Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides.

### **3.5 Special precautions for use**

This veterinary medicinal product does not contain any antimicrobial preservative.

#### Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target bacteria at farm level, or at local/regional level. Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to tulathromycin and may decrease the effectiveness of treatment with other macrolides, lincosamides and group B streptogramins due to the potential for cross resistance (MLSB resistance).

Since many NSAIDs possess the potential to induce gastrointestinal ulceration, especially in aged cattle and young calves, concomitant use of the veterinary medicinal product with other anti-inflammatory drugs (NSAIDs) or steroidal anti-inflammatory drugs (e.g., corticosteroids) should be avoided within the first 24 hours of treatment. Afterwards concurrent treatment with NSAIDs and steroidal anti-inflammatory drugs should be closely monitored. The use of the veterinary medicinal product (that contains ketoprofen) in aged animals or animals less than 6 weeks should be based on a benefit/risk assessment of the responsible veterinarian.

Avoid use in dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

Intra-arterial and intra-venous injection should be avoided.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- This veterinary medicinal product may cause hypersensitivity (allergy). People with known hypersensitivity to tulathromycin, ketoprofen, or to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental spillage onto skin, wash the skin immediately with soap and water.

- This veterinary medicinal product may cause adverse effects after dermal exposure and self-injection. Take care to avoid skin contact and accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
- NSAIDs, such as ketoprofen, may affect fertility and be harmful for the unborn child. Pregnant women, women intending to conceive and men planning to have children should use extreme caution while handling this veterinary medicinal product.
- This veterinary medicinal product is irritating to eyes. Avoid contact with the eyes. In case of accidental eye exposure, flush the eyes immediately with clean water. If irritation persists, seek medical advice and show the package leaflet to the physician.
- Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle:

Very common (>1 animal / 10 animals treated):	injection site pain <sup>1</sup> injection site swelling <sup>1,2</sup> injection site reaction <sup>2</sup> injection site oedema <sup>2</sup> injection site fibrosis <sup>2</sup> injection site haemorrhage <sup>2</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	digestive tract disorder renal disorder hypersensitivity reactions (e.g. anaphylaxis, dyspnoea, collapse) <sup>3</sup>

<sup>1</sup> May persist for up to 32 days after injection.

<sup>2</sup> Pathomorphological injection site reactions are present for approximately 32 days after injection.

<sup>3</sup> In case of such an allergic or anaphylactic reaction, appropriate symptomatic treatment should be administered immediately.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation:

Laboratory studies with tulathromycin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Studies with ketoprofen in laboratory species (rats, mice and rabbits) have not produced any evidence of teratogenic effects, but effects on fertility, maternal toxicity and embryotoxicity has been observed. There are known adverse class-effects of NSAIDS and other prostaglandin inhibitors on pregnancy and/or embryofetal development. The safety of tulathromycin and ketoprofen combination in the target species has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not use concurrently with other diuretics, nephrotoxic veterinary medicinal products or anticoagulants.

### **3.9 Administration routes and dosage**

Subcutaneous use.

A single subcutaneous injection of 2.5 mg tulathromycin/kg bodyweight and 3 mg ketoprofen/kg bodyweight (equivalent to 1 ml/40 kg bodyweight). For treatment of cattle over 400 kg bodyweight, divide the dose so that no more than 10 ml are injected at one site.

To ensure correct dosage bodyweight should be determined as accurately as possible to avoid underdosing.

For any respiratory disease, it is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection. If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed, using another antibiotic, and continued until clinical signs have resolved.

If there is persistent elevated body temperature 24 hours after treatment initiation, the responsible veterinarian must evaluate the necessity of further anti-pyretic treatment.

The stopper may be safely punctured up to 20 times. When treating groups of animals in one run, use a draw-off needle that has been placed in the vial stopper or an automatic syringe to avoid excessive broaching of the stopper. The draw-off needle should be removed after treatment.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

At dosages of 3 and 5 times the recommended dose transient signs of injection site pain and/or swelling which in some instances lasted until day 32. Additionally, transient signs attributed to injection site discomfort (pain) were observed and included restlessness, head-shaking, pawing the ground, and

brief decrease in feed intake. Microscopic mucosal erosions of the pylorus of the abomasum were observed at 3 and 5 times the recommended dose. Repeated administration can result in gastric toxicity. Mild myocardial degeneration has been observed in cattle receiving 5 to 6 times the recommended dose.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

*To be completed in accordance with national requirements.*

### **3.12 Withdrawal periods**

Meat and offal: 50 days.

Not authorised for use in cattle producing milk for human consumption.

Do not use in pregnant animals, which are intended to produce milk for human consumption, within 2 months of expected parturition.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QJ01FA99.**

### **4.2 Pharmacodynamics**

Tulathromycin is a semi-synthetic macrolide antimicrobial agent, which originates from a fermentation product. It differs from many other macrolides in that it has a long duration of action that is, in part, due to its three amine groups; therefore, it has been given the chemical subclass designation of triamilide.

Macrolides are bacteriostatic acting antibiotics and inhibit essential protein biosynthesis by virtue of their selective binding to bacterial ribosomal RNA. They act by stimulating the dissociation of peptidyl-tRNA from the ribosome during the translocation process.

Tulathromycin possesses *in vitro* activity against *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* the bacterial pathogens most commonly associated with bovine respiratory disease. Increased minimum inhibitory concentration (MIC) values have been found in some isolates of *Histophilus somni*.

The Clinical and Laboratory Standards Institute CLSI has set the MIC clinical breakpoints for tulathromycin against *M. haemolytica*, *P. multocida*, and *H. somni* of bovine respiratory origin, as  $\leq 16$   $\mu\text{g/ml}$  susceptible and  $\geq 64$   $\mu\text{g/ml}$  resistant. CLSI has also published clinical breakpoints for tulathromycin based on a disk diffusion method (CLSI document VET08,4th ed, 2018). Neither EUCAST nor CLSI have developed standard methods for testing antibacterial agents against veterinary *Mycoplasma* species and thus no interpretative criteria have been set.

Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB resistance); by enzymatic inactivation; or by macrolide efflux. MLSB resistance may be constitutive or inducible. Resistance among the BRD pathogens may be chromosomal or plasmid-encoded and may be transferable if associated with transposons, plasmids, integrative and conjugative elements. Additionally, the genomic plasticity of *Mycoplasma* is enhanced by the horizontal transfer of large chromosomal fragments.

In addition to its antimicrobial properties, tulathromycin demonstrates immunomodulating and anti-inflammatory actions in experimental studies. In bovine polymorphonuclear cells (PMNs; neutrophils), tulathromycin promotes apoptosis (programmed cell death) and the clearance of apoptotic cells by macrophages. It lowers the production of the pro-inflammatory mediators leukotriene B4 and CXCL-8 and induces the production of anti-inflammatory and pro-resolving lipid lipoxin A4.

Ketoprofen is a substance belonging to the group non-steroidal anti-inflammatory drugs (NSAIDs). Ketoprofen has anti-inflammatory, analgesic and antipyretic properties. Not all aspects of its mechanism of action are known. Effects are obtained partially by the inhibition of prostaglandin and leukotriene synthesis by ketoprofen, acting on cyclooxygenase and lipoxygenase respectively. The formation of bradykinin is also inhibited. Ketoprofen inhibits thrombocyte aggregation.

### 4.3 Pharmacokinetics

When subcutaneously co-administered in the combination formulation, at 2.5 mg tulathromycin/kg body weight, the maximum concentration ( $C_{max}$ ) in plasma was approximately 0.4  $\mu\text{g/ml}$ , this was achieved approximately 3 hours post-dosing ( $T_{max}$ ). Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life ( $t_{1/2}$ ) of 85 hours in plasma.

Furthermore, after subcutaneous injection of the tulathromycin-ketoprofen combination, the  $AUC_{(0-t)}$  of tulathromycin has been shown to be bioequivalent to the  $AUC_{(0-t)}$  after subcutaneous injection of tulathromycin 100 mg/ml for cattle. The combination had a slightly lower tulathromycin  $C_{max}$  and the rate of absorption was decreased in comparison with the administration of the compounds separately.

Regarding ketoprofen, following administration of the combination product, at 3 mg ketoprofen/kg body weight, the pharmacokinetics of ketoprofen are driven by flip-flop kinetics. The mean  $C_{max}$  in plasma was 2  $\mu\text{g/ml}$ , which was achieved at 4 hours on average. The terminal half-life of ketoprofen is dominated by the slow absorption and was estimated at 6.8 hours.

Furthermore, after subcutaneous injection of the tulathromycin-ketoprofen combination, there was a delay in the absorption, with a lower ketoprofen

peak concentration, and a longer elimination half-life, as compared with the compound alone.

Ketoprofen in the combination product is a racemic mixture of two enantiomers, S(+) and R (-). In-vitro models suggest that the S(+) enantiomer is 250 times more potent than the R(-) enantiomer. Inversion of R-ketoprofen to S-ketoprofen has been reported in cattle to be 31% following intravenous dosing of R-ketoprofen.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: 56 days.

### **5.3 Special precautions for storage**

Do not freeze.

### **5.4 Nature and composition of immediate packaging**

Type I amber glass vial with a fluoropolymer coated chlorobutyl rubber stopper and an aluminium overseal.

#### Pack sizes:

Cardboard box containing 1 vial of 50 ml  
Cardboard box containing 1 vial of 100 ml  
Cardboard box containing 1 vial of 250 ml

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

Medicines should not be disposed of via wastewater or household waste.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium S.A.  
2nd Floor, Building 10  
Cherrywood Business Park  
Loughlinstown  
Dublin 18  
D18 T3Y1  
Ireland

**7. MARKETING AUTHORISATION NUMBER**

Vm 60021/3060

**8. DATE OF FIRST AUTHORISATION**

01 September 2020

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

February 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

*Gavin Hall*

Approved: 26 February 2025